|
DOR BioPharma Has SPA Clearance From FDA To Start Confirmatory Phase 3 Clinical Trial Of OrBec(R) In GI GVHD (Medical News Today) |
 |
 |
|
DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB) announced that it has reached agreement with the US Food and Drug Administration (FDA) on the design of a confirmatory, pivotal Phase 3 clinical trial evaluating its lead product orBec(R) for the treatment of acute gastrointestinal Graft-versus-Host Disease (GI GVHD). read more |
|
Santa Cruz doctor helps save lives of family who ate poisonous ... - San Jose Mercury News |
|
|
|
None of the patients underwent transplants. All recovered but one, the 83-year-old grandmother. Her liver recovered but she succumbed to kidney failure. ... read more |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
